Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 4/20 | 0.59 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.59 |
| ▸ | IKBKB | O14920 | 11/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.44 |
| ▸ | MELK | Q14680 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612106 | 0.88 | PTPN1 (0.48) | CDC7DBF4MELK | |
| SCHEMBL613722 | 0.85 | KDM4E (0.52) | CDC7DBF4IKBKBMELK | |
| SCHEMBL612250 | 0.85 | IKBKB (0.70) | CDC7DBF4IKBKBJAK2CCNE1 | |
| SCHEMBL613690 | 0.81 | CDC7 (0.59) | CDC7DBF4IKBKBJAK2CCNE1 | |
| SCHEMBL613122 | 0.79 | CDC7 (0.57) | CDC7DBF4IKBKBJAK2CCNE1 | |
| SCHEMBL614144 | 0.77 | CDC7 (0.54) | CDC7DBF4IKBKBJAK2CDK2 | |
| SCHEMBL612267 | 0.75 | CDC7 (1.00) | CDC7DBF4IKBKBJAK2CCNE1 | |
| SCHEMBL614262 | 0.74 | CDC7 (0.65) | CDC7DBF4IKBKBJAK2CCNE1 | |
| SCHEMBL8239558 | 0.74 | PTPN1 (0.62) | IKBKB | |
| SCHEMBL611492 | 0.71 | IKBKB (0.52) | CDC7DBF4IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403857-B1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2403857-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010101302-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | CDC7, CDK7, DTYMK | CDC7 1/4885DBF4 593/4885IKBKB 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.